Previous 10 | Next 10 |
home / stock / azn / azn articles
Sunday, Nurix Therapeutics Inc (NASDAQ:NRIX) announced the presentation of updated clinical data for NX-5948, an orally bioavailable degrader of Br...
AstraZeneca plc’s (NASDAQ:AZN) cancer drug, Imfinzi (durvalumab), in conjunction with standard chemotherapy, has now received endorsement fro...
AstraZeneca Plc (NASDAQ:AZN) released data from the ECHO Phase 3 trial of Calquence (acalabrutinib) plus bendamustine and rituximab compa...
AstraZeneca (NASDAQ:AZN) has outperformed the market over the past 5 years by 2.26% on an annualized basis producing an average annual return of 15...
Tuesday, the FDA approved Amgen Inc (NASDAQ:AMGN) Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to AstraZeneca Plc’s (NASDA...
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March...
On Tuesday, AstraZeneca Plc (NASDAQ:AZN) said the survival results did not reach statistical significance in the overall trial population...
Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers struggling to fund late-stage...
On Thursday, Tango Therapeutics Inc. (NASDAQ:TNGX) announced that it will discontinue the development of its TNG348 program. “...
News, Short Squeeze, Breakout and More Instantly...
2024-07-20 00:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 08:30:07 ET Jefferies analyst issues HOLD recommendation for AZN on July 2, 2024 06:20AM ET. The previous analyst recommendation was Hold. AZN was trading at $77.94 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...